Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg
dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of
levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
Phase:
Phase 2
Details
Lead Sponsor:
Avanir Pharmaceuticals
Collaborator:
Michael J. Fox Foundation for Parkinson's Research